A Review of Three New Anti-Interleukin-5 Monoclonal Antibody Therapies for Severe Asthma

Cureus
doi 10.7759/cureus.3216
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Cureus, Inc.

Related search

Anti-Interleukin-5 Therapy in Severe Asthma

European Respiratory Review
PulmonaryRespiratory Medicine
2013English

A Meta-Analysis of Anti-Interleukin-13 Monoclonal Antibodies for Uncontrolled Asthma

PLoS ONE
Multidisciplinary
2019English

Comparison of Anti-Interleukin-5 Therapies in Patients With Severe Asthma: Global and Indirect Meta-Analyses of Randomized Placebo-Controlled Trials

Clinical and Experimental Allergy
AllergyImmunology
2016English

Pharmacokinetic and Pharmacodynamic Properties of Canakinumab, a Human Anti-Interleukin-1β Monoclonal Antibody

Clinical Pharmacokinetics
Pharmacology
2012English

Anti-Antibody Activity of a Monoclonal Macroglobulin

Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
1971English

Multispecificity of a Recombinant Anti-Ras Monoclonal Antibody

Journal of Molecular Recognition
Structural BiologyMolecular Biology
2017English

Prs61 - Assessment of Asthma-Diagnosed Population Eligible for New Monoclonal Antibody Therapy in Veneto Region

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Benralizumab: A Unique IL-5 Inhibitor for Severe Asthma

Journal of Asthma and Allergy
ImmunologyPulmonaryAllergyRespiratory Medicine
2016English

Crystal Structure of an Anti-Interleukin-2 Monoclonal Antibody Fab Fragment Complexed With an Antigenic Nonapeptide

Acta Crystallographica Section A Foundations of Crystallography
2000English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy